Health

Eli Lilly Agreed to Buy Calytrix Bio for Up to $1.5 Billion, Its Latest Deal in a $32 Billion Year

A $32 billion acquisition year rests on an $11 billion quarterly cash engine, but the deal headlines are "up to" figures and the balance sheet is already thinning. Whose money moves: anyone holding LLY at 31 times forward earnings into December 7 and January.

Vincent JiangVincent Jiangthree-minute read
Share
Eli Lilly chair and chief executive David A. Ricks, arms folded, in a blue suit and open collar
David A. Ricks, Eli Lilly's chair and chief executive. Lilly has agreed to buy Calytrix Bio for up to $1.5 billion, part of a $32 billion acquisition year in which its own filings show cash on hand falling.

Eli Lilly−2.15% — Eli Lilly, down 2.15 percent today agreed to buy Calytrix Bio, a closely held developer of treatments for rare blood cancers, in a deal worth up to $1.5 billion, the latest move in a $32 billion wave of acquisitions this year as the drugmaker builds out cancer and immunology businesses ahead of the patent cliff on Zepbound and Mounjaro 1. Days earlier, on November 16, it signed agreements with Stipple Bio and Calytrix carrying a combined potential value of about $7.4 billion, including milestone-contingent payments 2.

How much of that headline is cash versus promise is exactly what the filings do not itemize. Bloomberg reports Lilly has stuck to earlier-stage, cheaper deals 1, and none of what it has bought this year has reached approval, as far as the record shows 1.

The cash engine is real, and it is already running down

The checkbook behind the spree is genuine. Lilly's third-quarter revenue rose 39% to $24.4 billion, with volume up 53% offsetting a 15% slide in realized prices 3. Operating cash flow hit $11.4 billion in the quarter, more than four times the $2.5 billion of late 2024, per its SEC filings 5.

Eli Lilly's quarterly operating cash flow more than quadrupled since late 2024

The quarterly cash engine more than quadrupled since late 2024

0B5B10B15BQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '2611.4B
Data
Operating cash flow
Q4 '242.47B
Q1 '251.67B
Q2 '253.09B
Q3 '258.84B
Q4 '253.23B
Q1 '265.33B
Q2 '2610.69B
Q3 '2611.4B
Quarterly operating cash flow, USD billions, from Eli Lilly's SEC filings5

But the filings also show the pile thinning. Cash on the balance sheet fell from $9.8 billion in September 2025 and $8.95 billion at mid-2026 to $4.9 billion at the end of September, while debt stood at about $49.5 billion 5. What has not left yet is the promise side: the largest single check of 2026 is just above $7 billion, and Calytrix's headline $1.5 billion is an "up to" figure 1.

Cash on hand has fallen by half since September 2025 while debt climbed to $49.5 billion

  • Cash on hand
  • Total debt
$0B$20B$40B$60BQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Data
Cash on handTotal debt
Q3 '24$3.37B$31.12B
Q4 '24$3.27B$33.64B
Q1 '25$3.09B$38.52B
Q2 '25$3.38B$39.9B
Q3 '25$9.79B$42.51B
Q4 '25$7.27B$42.5B
Q1 '26$5.28B$43.37B
Q2 '26$8.95B$54.91B
Q3 '26$4.89B$49.5B
Cash and total debt at quarter end, USD billions, from Eli Lilly's SEC filings. Cash peaked at $9.8 billion at the end of September 2025 and stood at $4.9 billion a year later; debt peaked at $54.9 billion in June 2026.6

The deal charges are already inside the guidance

The bill for acquired research is already in the guidance: the third quarter carried $4.57 a share of acquired in-process research and development charges, the accounting line where deal costs hit earnings, and the full-year EPS guide of $35 to $36 includes them 3.

The market is marking down the acquirer

Lilly's stock closed at $1,382.75 on November 18, down 2.32%, a third straight loss and 6.27% below its November 16 high of $1,475.25 2. At that price the shares trade near 31 times forward earnings against a 5-year average of 40x, and Barclays'−1.00% — Barclays, down 1.00 percent today raised $1,550 target leaves about 9% upside 3.

Whether the contingent payments end up settled in cash or in shares is not disclosed; the open question is whether Lilly is funding a decade-ahead pipeline with an $11 billion quarterly cash engine, or with a stock the market is repricing 1. Management's own answer is history: Prozac's patent expiry sent Lilly into what Bloomberg calls a dark period, and the spending is insurance against a repeat, with roughly a decade left on the GLP-1 patents 1.

December 7 and January are the ledger dates

Innovation Day on December 7 is where management must show growth beyond obesity, and January's first 2027 guidance must show volume still outrunning falling prices 3. The cyber-extortion claims around a third-party vendor, which Lilly says did not touch its systems, are noise next to that 2. The number to watch is not the deal headlines. It is whether $11 billion a quarter of operating cash flow can absorb a $32 billion year of "up to" promises without another draw on debt 5.

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Loading LLY

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    GE HealthCare's manganese MRI agent matched gadolinium, a route past China's rare earths

    About 65 million contrast-enhanced MRI scans a year run on gadolinium, a rare earth whose export China licenses. A manganese substitute that matched the incumbent in GE HealthCare's Phase 2 trial opens a route off that chain for the company's highest-margin segment, if Phase 3 holds.

    Health

    Abridge lost AI scribing to Microsoft and Epic; its next market has a $100 million price from Wolters Kluwer

    Microsoft and Epic took two of every three new AI-scribe dollars this year, and Abridge, which built that market, is selling what comes after the note. The decision-support category it is moving into just got a public price, Wolters Kluwer's $100 million AgileMD deal, and that price is what Abridge's $6.69 billion private mark has to outrun.

    Health

    CMS's CRUSH rule reaches past Medicare into Molina's $42 billion Medicaid book

    The November 18 rout priced the proposal as a UnitedHealth-Humana Medicare bill. Molina is leaving that business, so for it the rule's weight falls on the Medicaid audit duties covering the $42 billion premium book that carries its $9.50 2027 earnings framework.

    Health

    AstraZeneca commits $200 million to Tempus AI through 2031 but can walk away for the shortfall

    A five-year, $200 million renewal from AstraZeneca gives Tempus AI a revenue floor it can book, filed days before a shareholder vote on a stock-funded acquisition, but the contract lets the drugmaker quit early by paying only the shortfall.

    Health

    OpenEvidence CEO tells medical students to take paper exams as OpenAI and Anthropic give doctors AI free

    Daniel Nadler built a $15 billion company on giving doctors AI answers free. On Monday he warned the doctors still training on his tool that AI erodes the skill that makes an answer worth having.

    Health

    Molina Healthcare jumps 8% on a CMS work-rule delay; director Steven Orlando sold 702 shares at $227.33

    A CMS work-rule delay bought Molina's Medicaid book time, not margin, and insiders including director Steven Orlando sold into the strength. New buyers are paying roughly 24 times a 2027 framework that is not yet guidance and must still be earned in February.

    Subscribe to TheInference for free